Cargando…

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound

Detalles Bibliográficos
Autores principales:	Ranard, Benjamin L., Vodovotz, Yoram, Asgari, Shadnaz, Megjhani, Murad, Chow, Carson C., Park, Soojin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	W.B. Saunders 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930205/ http://dx.doi.org/10.1016/j.jcrc.2022.154210

Ejemplares similares

Identification of Endotypes of Hospitalized COVID-19 Patients
por: Ranard, Benjamin L., et al.
Publicado: (2021)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model
por: Day, Judy D., et al.
Publicado: (2021)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Heart rate variability and adrenal size provide clues to sudden cardiac death in hospitalized COVID-19 patients
por: Ranard, Benjamin L., et al.
Publicado: (2022)

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
por: Periyasamy, P., et al.
Publicado: (2023)

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022)

COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
por: Alshanqeeti, Shatha, et al.
Publicado: (2022)

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
por: Sun, Fangfang, et al.
Publicado: (2022)

Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
por: Yang, Da‐Wei, et al.
Publicado: (2023)

In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach
por: Bartha, Ferenc A., et al.
Publicado: (2022)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid
por: Wang, Yu, et al.
Publicado: (2022)

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
por: Fishbane, Steven, et al.
Publicado: (2022)

The Path to Paxlovid
por: Halford, Bethany
Publicado: (2022)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

A sustainable synthesis of the SARS-CoV-2 M(pro) inhibitor nirmatrelvir, the active ingredient in Paxlovid
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
por: Niraj, Niraj, et al.
Publicado: (2022)

A 1-Pot Synthesis of the SARS-CoV-2 M(pro) Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid
por: Caravez, Juan C., et al.
Publicado: (2022)

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
por: Li, Yixian, et al.
Publicado: (2023)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
por: Wang, Lindsey, et al.
Publicado: (2022)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
por: Panza, Francesca, et al.
Publicado: (2023)

Mathematical Modeling of Early Cellular Innate and Adaptive Immune Responses to Ischemia/Reperfusion Injury and Solid Organ Allotransplantation
por: Day, Judy D., et al.
Publicado: (2015)

Heart rate and heart rate variability as a prognosticating feature for functional outcome after cardiac arrest: A scoping review
por: Kwon, Soon Bin, et al.
Publicado: (2023)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

COVID 19, Paxlovid and the lesson from rare genetic diseases with naturally occurring protection from SARS-CoV-2 infection
por: Calò, Lorenzo A., et al.
Publicado: (2022)

The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
por: Zhong, Weijie, et al.
Publicado: (2022)

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
por: Park, Hanul, et al.
Publicado: (2022)

Paxlovid™ jetzt direkt an Patienten abgeben
por: Zimmermann, Gerd W.
Publicado: (2022)

Paxlovid-Induced Symptomatic Bradycardia and Syncope
por: Ganipisetti, Venu M, et al.
Publicado: (2023)

CARDIOGENIC SHOCK DUE TO PAXLOVID INTERACTION
por: Enstrom, Cate, et al.
Publicado: (2023)

Serotonin Syndrome Precipitated by Paxlovid Initiation
por: Nasser, Nicholas G, et al.
Publicado: (2023)

A novel low-complexity digital filter design for wearable ECG devices
por: Asgari, Shadnaz, et al.
Publicado: (2017)

Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2
por: Reina, Jordi, et al.
Publicado: (2022)

Genetic Surveillance of SARS-CoV-2 M(pro) Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
por: Lee, Jonathan T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5816t4gu609cs3u3kr66e5nh0